ecrin-mdr-crcClinical2015Squamous Cell Carcinoma of Head and NeckCarcinomaRenal Cell Carcinoma (RCC) (Phase ll Only)GlioblastomaCarcinoma, Renal CellOvarian Carcinoma-Enrollment CompletedColorectal Cancer (CRC)-Enrollment CompletedSquamous Cell Carcinoma of the Head and Neck (SCCHN)Glioblastoma (GBM) (Phase ll Only)-Enrollment CompletedSquamous Cell Carcinoma Of The Head And Neck (scchn)Squamous Cell Carcinoma Of Head And NeckRenal Cell Carcinoma (rcc) (phase Ll Only)Colorectal Cancer (crc)-enrollment CompletedCarcinomaGlioblastoma (gbm) (phase Ll Only)-enrollment CompletedGlioblastomaCarcinoma, Renal CellOvarian Carcinoma-enrollment CompletedInterventionalhttps://newmdr.ecrin.org/Study/2181728United States1NivolumabOpdivoECRIN MDRCompletedfalseA Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsThis is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.2015-01-152181728NCT02335918